8:00 am Coffee & Networking

8:50 am Chair’s Opening Remarks

• Nina Horowitz Chief Executive Officer, ImmuneBridge

Strengthening Donor Retention & Optimizing Cryopreservation to Minimize Supply Chain Risks

9:00 am Tackling Donor Recallability for Long-Term Success in Cell Therapy

• Nairika Meshgin Senior Coordinator, Clinical Supply Chain, Genentech

9:30 am Cryopreservation Strategies to Reduce Cold Chain Variability & Minimize Product Degradation

• Katie Pollock Associate Director & Head of Formulation & Cryobiology, Bristol Myers Squibb

10:00 am Roundtable Discussion: Enhancing Allogeneic Cell Therapy Success by Optimizing Donor Selection Early in Development

• Nina Horowitz Chief Executive Officer, ImmuneBridge
• Tawni Koutchesfahani Bio-Operations Executive, Stealth Mode

10:45 am Morning Break & Networking

Updating Our Understanding of Regulations to Drive Long-Term Clinical Success

11:45 am *New Data* Leveraging Non-Animal Models to Improve Donor Selection & Product Reproducibility

• Aaron Goldman Director, Instructor in Medicine, Mass General Brigham

12:15 pm Standardized Terminology & Labeling Using the ISBT 128 Standard

• Robin Wilkinson Deputy Technical Director, ICCBBA

12:45 pm Lunch Break & Networking

Boosting Product Quality & Investor Appeal by Addressing Cell Type Differences

1:45 pm Panel Discussion: Navigating Cell Type Differences to Optimize Donor Selection & Manufacturing

• Jeff Liter President & Chief Executive Officer, Luminary Therapeutics
• Meghan Eberhardt Director, Analytical Development, Artiva Biotherapeutics

2:30 pm Roundtable: Building Investor Confidence Through Scalable Donor Strategies in Allogeneic Cell Therapy

• Spring Sun Director, External Manufacturing, Allogene Therapeutics

3:15 pm Afternoon Break & Networking

Pulling Back the Curtain on Donor Screening Strategies to Accelerate Progress Together

4:15 pm Building Predictive Donor Screening for Allogeneic Cell Therapies from Biomarker Discovery to Clinical Validation

• Hubert Tseng Principal Scientist, Immuno-Oncology, Genentech

4:45 pm Advancing Rapid Assays for Pre-Identifying Top Donors

• Henri Bayle Chief Scientific & Development Officer, Co-founder, NKILT Therapeutics

5:15 pm End of the 3rd Donor Selection & Cell Source Summit